Trial Profile
Neoadjuvant Immunotherapy With Durvalumab in Combination With Tremelimumab in Patients With Muscle-invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms NITIMIB
- 16 Jun 2020 Status changed from active, no longer recruiting to discontinued due to low accrual.
- 13 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2018 Planned End Date changed from 1 Mar 2027 to 1 Mar 2025.